molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR
Search Results
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
Presented by: Dustin A. Deming
A Novel Approach Using Sorafenib in Alpha Fetoprotein–Producing Hepatoid Adenocarcinoma of the Lung
Tatjana Gavrancic and Yeun-Hee Anna Park
the literature Examine the use of sorafenib in combination with platinum-based doublet chemotherapy in EGFR wild-type HAL H epatoid adenocarcinoma of the lung (HAL) is an extremely rare cancer that lacks treatment guidance and has a poor
Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer
Philip E. Lammers and Leora Horn
molecular mutation thought to drive tumor growth. 4 However, only patients with epidermal growth factor receptor (EGFR) mutations (approximately 10%-15%) or anaplastic lymphoma kinase (ALK) rearrangements (approximately 5%) have an FDA-approved therapy
Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer
Ryan D. Gentzler and Jyoti D. Patel
erlotinib and crizotinib for epidermal growth factor receptor ( EGFR )-mutated and anaplastic lymphoma kinase ( ALK )-rearranged NSCLC, respectively. This article focuses on the first-line treatment of NSCLC with no identifiable mutations with FDA
Multigene Assays in Metastatic Colorectal Cancer
Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih
, 8 For example, one of the major advances in the past 5 to 7 years has been the interrogation of the epidermal growth factor receptor (EGFR) pathway vis-à-vis cetuximab-based therapy in colorectal cancer. Retrospective analyses of tissue obtained
Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances
Dung T. Le and Elizabeth M. Jaffee
; DC, dendritic cell; EGFR, epidermal growth factor receptor; GM-CSF, granulocyte-macrophage colony-stimulation factor; HER2, human epidermal growth factor receptor-2; IL, interleukin; PD-1, programmed death-1; VEGF, vascular endothelial growth factor
A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee
primary (CK7+, CK20-, TTF1+). The patient's tumor was negative for both KRAS and epidermal growth factor receptor (EGFR)–activating mutations. PET/CT showed the FDG-avid mass in the right upper lobe of the lung, and metastases to the bone, liver, and
Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling
Adam C. Powell, Elifnur Yay Donderici, Nicole J. Zhang, Shaun P. Forbes, Julie Wiedower, Amy C. McNeal, and Mark D. Hiatt
NSCLC require patients to have a specific biomarker profile detectable via CGP—negativity for ALK rearrangement (fusions) and EGFR mutations (alterations L858R/EXON19 deletions)—or to have had prior toxicity or progression on oral therapies targeting
Multigene Sets for Clinical Application in Glioma
John F. de Groot, Erik P. Sulman, and Kenneth D. Aldape
rates of epidermal growth factor receptor (EGFR) amplification and chromosome 10 loss. 12 , 16 , 17 Based on an examination of microarray studies from several independent studies, followed by validation in formalin-fixed paraffin-embedded (FFPE) samples
Updates to Treatment of Recurrent Metastatic Head and Neck Cancers
Presented by: Cristina P. Rodriguez
. Investigational Combinations in the First-Line Setting Dr. Rodriguez discussed several promising early combinations of EGFR monoclonal antibodies and ICIs in the first-line setting for recurrent/metastatic HNSCC. These combinations appear to have a synergistic
